Lonza is establishing a strategic biomanufacturing base in China using GE Healthcare Solutions. With the new facility, Lonza is responding to growing demand for a high-quality CDMO in the Chinese market. The two companies will work closely on the design of the 17,000 m2 site, which will include 6,500 m2 of lab space and one KUBio facility. With more than 20 successful FDA approvals for biologics, combined with international regulatory expertise, Lonza will now be able to offer the same high standards in China as it does elsewhere. Lonza plans to hire and train a significant number of staff for this site.Key requirements:
https://www.lonza.com/jobs/R22931
- Have cell culture working experience in a biologics industry
We are currently looking for Product Marketing Manager. You will be responsible for China product marketing strategy in support of the business plan for Bioscience for all product lines(endotoxin, cell biology, and transfection) and work in close conjunction with field sales representatives to support the rapid growth of sales in China.
Key requirements:
- Master or PhD in biology. Experiences in cell therapy will be greatly preferred.
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C, page-185
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.015(1.41%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.09 | $1.05 | $4.232M | 3.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 61694 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.06 | 45910 | 3 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.06 |
Change
-0.015 ( 0.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.09 | $1.05 | 969435 | ||
| Last updated 15.59pm 15/05/2024 ? | |||||
| MSB (ASX) Chart |